Skip to main content
SpringerLink
Log in

Clinical Presentation

  • Chapter
Neuroblastoma

Part of the book series: Pediatric Oncology ((PEDIATRICO))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abel F et al. (1999) Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer 81:1402–1409

    Article  PubMed  Google Scholar 

  • Ambros I et al. (1996) Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 334:1505–1511

    Article  PubMed  Google Scholar 

  • Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492–504

    Article  PubMed  Google Scholar 

  • Berthold F, Harms D, Lampert F, Niethammer D, Zieschang J (1990) Risk factors in neuroblastoma of infants. Contrib Oncol 41:101–117

    Google Scholar 

  • Berthold F et al. (1992a) Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 14:207–215

    PubMed  Google Scholar 

  • Berthold F et al. (1992b) Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma. Eur J Cancer 28A:1950–1954

    Article  PubMed  Google Scholar 

  • Berthold F et al. (1994) Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 16:107–115

    PubMed  Google Scholar 

  • Berthold F et al. (1998) Are spontaenous regressions of neuroblastoma delayed embryofetal involutions? Sind Spontanregressionen beim Neuroblastom verspätete embryofetale Involutionen? In: Hein E, Schwarz, Stuttgard R (eds) Spontanremissionen in der Onkologie: theoretische Modelle und klinische Befunde. Schattauer, New York, pp 84–94

    Google Scholar 

  • Bown N et al. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954–1961

    PubMed  Google Scholar 

  • Brodeur GM et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477

    PubMed  Google Scholar 

  • Brodeur GM et al. (1997) Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93–101

    Article  PubMed  Google Scholar 

  • Castleberry RP et al. (1994) The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol 12:2378–2381

    PubMed  Google Scholar 

  • Cohn SL et al. (1995) Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 55:721–726

    PubMed  Google Scholar 

  • Combaret V et al. (1996) Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14:25–34

    PubMed  Google Scholar 

  • Combaret V et al. (1997) Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Br J Cancer 75:1151–1155

    PubMed  Google Scholar 

  • Combaret V et al. (2002) Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res 62:3646–3648

    PubMed  Google Scholar 

  • Cooper R et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features — a report from the Children's Cancer Group. Med Pediatr Oncol 36:623–629

    Article  PubMed  Google Scholar 

  • Cotterill SJ et al. (2000) Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group “Survey” 1982–1992. Eur J Cancer 36:901–908

    Article  PubMed  Google Scholar 

  • Cushing HSW (1927) The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol 3:203–216

    Google Scholar 

  • De Bernardi B et al. (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19:183–190

    PubMed  Google Scholar 

  • De la Monte SM et al. (1983) Nonrandom distribution of metastases in neuroblastic tumors. Cancer 52:915–925

    PubMed  Google Scholar 

  • Dluhy RG (2002) Pheochromocytoma: death of an axiom. N Engl J Med 346:1486–1488

    Article  PubMed  Google Scholar 

  • DuBois SG et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181–189

    Article  PubMed  Google Scholar 

  • Dulguerov P et al. (2001) Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2:683–690

    Article  PubMed  Google Scholar 

  • El Shafie M et al. (1983) Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 18:34–36

    PubMed  Google Scholar 

  • Evans AE et al. (1971) A proposed staging for children with neuroblastoma. Cancer 27:374–378

    PubMed  Google Scholar 

  • Evans AE et al. (1990) A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group. J Clin Oncol 8:678–588

    PubMed  Google Scholar 

  • Garaventa A et al. (2002) Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 13:956–964

    Article  PubMed  Google Scholar 

  • Geoerger B et al. (2001) Metabolic activity and clinical features of primary ganglioneuromas. Cancer 91:1905–1913

    Article  PubMed  Google Scholar 

  • Greenberg RE (1957) New diagnostic test for neural tumors in infancy: increased urinary excretion of 3-methoxy-4-hydroxymandelic acid and norepinephrin in a ganglioneuroma with chronic diarrhea. Pediatrics 24:683–684

    Google Scholar 

  • Guo C et al. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18:4948–4957

    PubMed  Google Scholar 

  • Hallstensson K et al. (1997) Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur J Cancer 33:1966–1970

    Article  PubMed  Google Scholar 

  • Hann HW, Bombardieri E (2000) Serum markers and prognosis in neuroblastoma: Ferritin, LDH, NSE. In: Brodeur G, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 371–381

    Google Scholar 

  • Hann HW et al. (1981) Biologic differences between neuroblastoma stages IV–S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med 305:425–429

    PubMed  Google Scholar 

  • Hann HW et al. (1985) Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 45:2843–2848

    PubMed  Google Scholar 

  • Hero B et al. (2001) Evaluation of catecholamine metabolites, MIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 36:220–223

    Article  PubMed  Google Scholar 

  • Hero B et al. (2002) Neuroblastoma preoperatively treated as nephroblastoma: Does inadequate therapy worsen the prognosis? Klin Padiatr 214:157–161

    Article  PubMed  Google Scholar 

  • Hero B et al. (2000) Regression in stage 2 and 3 infant neuroblastoma: results of the prospective German neuroblastoma trial. Adv Neuroblastoma Res. Abstract,15–18 May, Philadelphia, P20

    Google Scholar 

  • Hsiao RJ et al. (1990) Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 85:1555–1559

    PubMed  Google Scholar 

  • Hutchinson R (1907) On suprarenal sarcoma in children with metastases in the skull. Q J Med 1:33–38

    Google Scholar 

  • Ikeda H et al. (2002) Experience with international neuroblastoma staging system and pathology classification. Br J Cancer 86:1110–1116

    Article  PubMed  Google Scholar 

  • Jaffe R et al. (1984) The neuroectodermal tumor of bone. Am J Surg Pathol 8:885–898

    PubMed  Google Scholar 

  • Kaneko M et al. (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613–621

    Article  PubMed  Google Scholar 

  • Katzenstein HM et al. (2001) Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 19:1047–1055

    PubMed  Google Scholar 

  • Khan J et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673–679

    Article  PubMed  Google Scholar 

  • Kogner et al. (1993) Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol 21:317–322

    PubMed  Google Scholar 

  • Kramer K et al. (1997) Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma. Eur J Cancer 33:2090–2091

    PubMed  Google Scholar 

  • Krams M et al. (2002) Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 94:854–861

    Article  PubMed  Google Scholar 

  • Kushner BH et al. (1996) International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 14:2174–2180

    PubMed  Google Scholar 

  • Ladenstein R et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953–965

    PubMed  Google Scholar 

  • Ladenstein R et al. (2001) Prognostic significance of DNA ditetraploidy in neuroblastoma. Med Pediatr Oncol 36:83–92

    Article  PubMed  Google Scholar 

  • Lastowska M et al. (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080–3090

    PubMed  Google Scholar 

  • Lau L (2002) Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 19:79–89

    Article  PubMed  Google Scholar 

  • Laug WE et al. (1978) Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 62:77–83

    PubMed  Google Scholar 

  • Lilling G et al. (1994) Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 5:231–239

    PubMed  Google Scholar 

  • Look AT et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581–591

    PubMed  Google Scholar 

  • Marchand F (1891) Beiträge zur Kenntnis der normalen und pathologischen Anatomie der Glandula carotica und der Nebennieren. Virchows Arch 5:578

    Google Scholar 

  • Maris JM et al. (2001) Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 36:32–36

    Article  PubMed  Google Scholar 

  • Mason GA, Hart-Mercer J, Miller E (1957) Adrenalin-secreting neuroblastoma in an infant. Lancet 273:322–325

    Article  PubMed  Google Scholar 

  • Mathew P et al. (2001) Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 3:105–109

    Article  PubMed  Google Scholar 

  • Mora J et al. (2001) Neuroblastic and schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res 61:6892–6898

    PubMed  Google Scholar 

  • Ng YY, Kingston JE (1993) The role of radiology in the staging of neuroblastoma. Clin Radiol 47:226–235

    PubMed  Google Scholar 

  • Nickerson HJ et al. (2000) Favorable biology and outcome of stage IV–S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18:477–486

    PubMed  Google Scholar 

  • Norris MD et al. (1996) Expression of the gene for multidrugresistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231–238

    Article  PubMed  Google Scholar 

  • Pearson ADJ, Philipp T (2000) Prognosis of low-risk and high-risk neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 551–560

    Google Scholar 

  • Pepper W (1901) A study of congenital sarcoma of the liver and suprarenal with the report of a case. Am J Med Sci 121:287–299

    Google Scholar 

  • Plantaz D et al. (2001) Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91:680–686

    Article  PubMed  Google Scholar 

  • Powell JE et al. (1998) Neuroblastoma in Europe: differences in the pattern of disease in the UK. SENSE. Study group for the Evaluation of Neuroblastoma Screening in Europe. Lancet 352:682–687

    Article  PubMed  Google Scholar 

  • Rudnick E et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies: a report from the Children's Cancer Group Study. Med Pediatr Oncol 36:612–622

    Article  PubMed  Google Scholar 

  • Russo C et al. (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28:284–288

    Article  PubMed  Google Scholar 

  • Sauvat F et al. (2002) Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 94:2474–2480

    Article  PubMed  Google Scholar 

  • Schilling FH et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346:1047–1053

    Article  PubMed  Google Scholar 

  • Schwab M et al. (1983) Amplified DNA with limited homology to MYCN cellular oncogene is shared by human neuroblastoma cell lines and neuroblastoma tumor. Nature 305:245–248

    Article  PubMed  Google Scholar 

  • Seeger RC, Brodeur GM, Sather H (1985) Association of multiple copies of N-myc oncogene with rapid progression in neuroblastoma. N Engl J Med 313:1111–1116

    PubMed  Google Scholar 

  • Shimada H, Roald B (2000) Histology: tumors of the neuroblastoma group. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 341–354

    Google Scholar 

  • Shimada H et al. (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405–416

    PubMed  Google Scholar 

  • Shimada H et al. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372

    Article  PubMed  Google Scholar 

  • Shuster JJ et al. (1992) Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 15:295–303

    PubMed  Google Scholar 

  • Simon T et al. (2003) Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 39:1899–1903

    Article  PubMed  Google Scholar 

  • Simon T et al. (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22:3549–3557

    Article  PubMed  Google Scholar 

  • Spitz R et al. (2002) Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 34:299–305

    Article  PubMed  Google Scholar 

  • Spitz R et al. (2003a) FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol 41:30–35

    Article  PubMed  Google Scholar 

  • Spitz R et al. (2003b) Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 9:4835–4840

    PubMed  Google Scholar 

  • Stickler GB et al. (1959) Ganglioneuroma associated with chronic diarrhea and increased excretion of catecholamine. Proc Staff Meet Mayo Clin 34:548–549

    Google Scholar 

  • Suc A et al. (1996) Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 77:805–811

    Article  PubMed  Google Scholar 

  • Terpe HJ et al. (1994) Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Death Differ 1:123–128

    Google Scholar 

  • Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  Google Scholar 

  • Vandesompele J et al. (1998) Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 23:141–152

    Article  PubMed  Google Scholar 

  • Virchow R (1864) Hyperplasie der Zirbel und der Nebenniere. Die krankhaften Geschwulste, vols 11,18. Vorlesung 7.2.1863. Hirschwald, Berlin, pp 148–150

    Google Scholar 

  • Von Schweinitz D, Hero B, Berthold F (2002) The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 12:402–409

    Article  PubMed  Google Scholar 

  • White PS et al. (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2–36.3. Proc Natl Acad Sci USA, 92:5520–5524

    PubMed  Google Scholar 

  • Woods WG et al. (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041–1046

    Article  PubMed  Google Scholar 

  • Wright J (1910) Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 12:556–561

    Article  Google Scholar 

  • Yamamoto K et al. (1998) Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 16:1265–1269

    PubMed  Google Scholar 

  • Zeltzer PM et al. (1983) Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 2:361–363

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Frank Berthold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA

    Nai-Kong V. Cheung MD, PhD

  2. Department of Pediatrics and the Comprehensive Robert H. Lurie Cancer Center, Northwestern University, 2300 Children's Plaza, Chicago, IL, 60614, USA

    Susan L. Cohn MD

  3. Feinberg School of Medicine, Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL, 60614, USA

    Susan L. Cohn MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Berthold, F., Simon, T. (2005). Clinical Presentation. In: Cheung, NK.V., Cohn, S.L. (eds) Neuroblastoma. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26616-X_7

Download citation

  • DOI: https://doi.org/10.1007/3-540-26616-X_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40841-3

  • Online ISBN: 978-3-540-26616-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation